Postpartum IUD Use Up With Intracesarean Placement

Share this content:
Postpartum IUD Use Up With Intracesarean Placement
Postpartum IUD Use Up With Intracesarean Placement

(HealthDay News) -- The proportion of women using intrauterine devices (IUDs) at six months postpartum is higher for those undergoing intracesarean delivery placement versus those with planned interval IUD placement, according to a study published online June 5 in Obstetrics & Gynecology.

Erika E. Levi, M.D., M.P.H., from the Albert Einstein College of Medicine in Bronx, N.Y., and colleagues compared IUD use at six months postpartum among women who underwent intracesarean delivery IUD placement versus women who planned for interval IUD placement at six or more weeks postpartum. One hundred twelve women were randomized into the trial (56 in each group). Data on IUD use at six months postpartum were available for 98 women: 48 in the intracesarean delivery group and 50 in the interval group.

The researchers found that the proportion of women using an IUD at six months postpartum was significantly higher in women in the intracesarean delivery group versus the interval group (83 versus 64 percent; relative risk, 1.3). Of the 56 women in the interval IUD insertion group, 39 percent never received an IUD placement; 25, 9, and 5 percent failed to return for IUD placement, declined an IUD, and had a failed IUD placement, respectively.

"Intrauterine device placement at the time of cesarean delivery leads to a higher proportion of IUD use at six months postpartum when compared with interval IUD placement," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »